Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 12
Venture Financing 14
Melinta Therapeutics Raises USD67 Million in Series 4 Venture Financing 14
Melinta Therapeutics Secures Additional USD10 Million from Hercules Technology Growth Capital 15
Melinta Therapeutics Raises US$70 Million In Series 3 Financing 16
Rib-X Pharma Raises US$19 Million In First Tranche Of Series 2 Financing 17
Private Equity 19
Melinta Therapeutics to Raise Funds through Financing Round 19
Partnerships 20
Melinta Therapeutics Enters into Agreement with Menarini 20
Melinta Therapeutics Expands Agreement with Eurofarma Lab 21
Cempra Pharma Enters into Agreement with BARDA 22
Merger 23
Melinta Therapeutics and Cempra Merge 23
Licensing Agreements 25
Menarini Enters into Licensing Agreement with Melinta Therapeutics 25
Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 26
Equity Offering 27
Melinta Therapeutics Raises USD123.2 Million in Public Offering of Shares 27
Melinta Therapeutics Plans to Raise USD115 Million in Public Offering of Shares 29
Rib-X Pharma Withdraws IPO 30
Acquisition 31
Medicines Company Acquires Rempex Pharma For US$474 Million 31
Melinta Therapeutics Inc – Key Competitors 33
Melinta Therapeutics Inc – Key Employees 34
Melinta Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 07, 2018: Melinta Therapeutics reports third quarter 2018 financial results 36
Aug 07, 2018: Melinta Therapeutics Reports Second Quarter 2018 Financial Results 38
May 08, 2018: Melinta Therapeutics Reports First Quarter 2018 Financial Results 40
Mar 13, 2018: Melinta Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 42
Corporate Communications 44
Oct 31, 2018: Melinta Therapeutics announces appointment of Bruce L. Downey to Board of Directors 44
Oct 22, 2018: Melinta Therapeutics appoints John H. Johnson as Interim Chief Executive Officer 45
Sep 18, 2018: Melinta Therapeutics appoints Peter Milligan as Chief Financial Officer 46
Oct 31, 2017: Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company 47
Oct 31, 2017: Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization 48
Product News 51
10/30/2017: Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States 51
09/28/2017: The Medicines Company to Present Data On ORBACTIV (oritavancin) At IDWeek 2017 52
09/22/2017: Melinta Therapeutics to Participate in Two Upcoming Investor Conferences 53
08/30/2017: The Medicines Company Announces FDA Approval of VABOMERE (meropenem and vaborbactam) 54
08/29/2017: FDA approves new antibacterial drug 56
06/19/2017: Melinta Therapeutics Announces U.S. FDA Approval of Baxdela (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections 57
05/31/2018: Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018 58
05/30/2017: The Medicines Company to Present Data on Orbactiv at ASM Microbe 2017 59
04/23/2018: Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018 61
04/17/2017: The Medicines Company to Present Data on Orbactiv (oritavancin) at ECCMID 2017 62
04/16/2018: Melinta Therapeutics to Present New Findings from Pyrrolocytosine Candidate RX-P2382 at ECCMID 2018 64
01/29/2018: Melinta Therapeutics Launches Antibiotic Baxdela (delafloxacin) in the United States 65
Product Approvals 66
Mar 08, 2018: Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe 66
Feb 20, 2018: Melinta Therapeutics’ Commercial Partner Eurofarma Laboratories Submits Marketing Authorization Application for Delafloxacin in Argentina 67
Aug 02, 2017: Firma Provides Support Associated with FDA Approval of Melinta Therapeutics’ Baxdela (delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 68
Feb 21, 2017: The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam) 69
Clinical Trials 70
Nov 13, 2017: Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne 70
Oct 24, 2017: Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities 71
Oct 10, 2017: Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne 72
Oct 05, 2017: The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017 73
Oct 04, 2017: Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek 76
Sep 28, 2017: The Medicines Company to Present Data On VABOMERE (meropenem and vaborbactam) at IDWeek 2017 78
Sep 25, 2017: Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections 82
Sep 18, 2017: Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens 84
Jul 25, 2017: The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE 85
May 30, 2017: The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam 87
Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam 91
Feb 24, 2017: Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI 94
Other Significant Developments 96
May 11, 2018: Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance 96
Nov 03, 2017: Cempra Announces Preliminary Results of 2017 Stockholder Vote 97
Appendix 98
Methodology 98
About GlobalData 98
Contact Us 98
Disclaimer 98
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Melinta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 12
Melinta Therapeutics Raises USD67 Million in Series 4 Venture Financing 14
Melinta Therapeutics Secures Additional USD10 Million from Hercules Technology Growth Capital 15
Melinta Therapeutics Raises US$70 Million In Series 3 Financing 16
Rib-X Pharma Raises US$19 Million In First Tranche Of Series 2 Financing 17
Melinta Therapeutics to Raise Funds through Financing Round 19
Melinta Therapeutics Enters into Agreement with Menarini 20
Melinta Therapeutics Expands Agreement with Eurofarma Lab 21
Cempra Pharma Enters into Agreement with BARDA 22
Melinta Therapeutics and Cempra Merge 23
Menarini Enters into Licensing Agreement with Melinta Therapeutics 25
Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 26
Melinta Therapeutics Raises USD123.2 Million in Public Offering of Shares 27
Melinta Therapeutics Plans to Raise USD115 Million in Public Offering of Shares 29
Rib-X Pharma Withdraws IPO 30
Medicines Company Acquires Rempex Pharma For US$474 Million 31
Melinta Therapeutics Inc, Key Competitors 33
Melinta Therapeutics Inc, Key Employees 34
Melinta Therapeutics Inc, Subsidiaries 35
List of Figures
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9